Mach7 Technologies Ltd (ASX: M7T) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Mach7 Technologies Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $79.90 million
P/E Ratio 1,428.57
Dividend Yield 0.00%
Shares Outstanding 235.01 million
Earnings per share -0.026
Dividend per share N/A
Year To Date Return -43.09%
Earnings Yield 0.07%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Mach7 Technologies Ltd (ASX: M7T)
    Latest News

    a woman
    Capital Raising

    Why Mach7 Technologies is in a trading halt

    Mach7 Technologies Ltd (ASX: M7T) requests a trading halt pending a material announcement regarding a proposed capital raising.

    Read more »

    a woman
    Share Gainers

    Mach7 Technologies share price jumps 15% on quarterly update

    The Mach7 Technologies share price is climbing higher in Thursday trade following the release of a bullish quarterly update.

    Read more »

    a woman
    Share Market News

    Results: Mach7 share price wobbles after loss balloons by 40%

    The Mach7 Technologies Ltd (ASX: M7T) reported a 42% rising loss this morning in its financial year 2019 results.

    Read more »

    a woman
    Share Fallers

    Mach7 Technologies share price falls 3% lower on weak quarterly update

    The Mach7 Technologies Ltd (ASX: M7T) share price is currently trading 3% lower on the ASX after its Q4 2019…

    Read more »

    a woman
    Share Gainers

    ALL ORDINARIES finishes lower Tuesday: 8 shares you missed

    The S&P/ASX 200 (Index:^AXJO)(ASX:XJO) and ALL ORDINARIES (Index:^AXAO) (ASX:XAO) finished lower on Tuesday.

    Read more »

    a woman
    52-Week Highs

    Why the Mach7 Technologies share price is printing 52-week highs

    A contract win sees the Mach7 Technologies Ltd (ASX:M7T) share price surge higher in Tuesday trade.

    Read more »

    Frequently Asked Questions

    No,  this ASX small-cap share has never paid dividends.

    Mach7 Technologies has been listed on the ASX since 30 November 2005.

    M7T ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Mach7 Technologies Ltd

    Mach7 Technologies Ltd (ASX: M7T) is a medical imaging systems provider that develops innovative image management and viewing solutions for healthcare organisations. Its systems create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. This allows healthcare enterprises to identify, connect, and share diagnostic image and patient care intelligence.

    Mach7 has more than 150 customers in 15 countries and derives a majority of its revenue from North America.

    M7T Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    25 Feb 2026 $0.34 $0.00 0.00% 365,733 $0.34 $0.35 $0.33
    24 Feb 2026 $0.34 $-0.01 -2.86% 59,363 $0.35 $0.35 $0.34
    23 Feb 2026 $0.35 $-0.01 -2.82% 66,772 $0.35 $0.36 $0.35
    20 Feb 2026 $0.36 $0.01 2.86% 71,454 $0.35 $0.36 $0.34
    19 Feb 2026 $0.35 $0.01 2.90% 36,636 $0.36 $0.36 $0.35
    18 Feb 2026 $0.35 $-0.01 -2.86% 97,803 $0.35 $0.35 $0.34
    17 Feb 2026 $0.35 $-0.01 -2.82% 85,508 $0.36 $0.36 $0.35
    16 Feb 2026 $0.36 $0.00 0.00% 15,169 $0.36 $0.36 $0.36
    13 Feb 2026 $0.36 $-0.03 -7.89% 155,138 $0.38 $0.38 $0.36
    12 Feb 2026 $0.38 $-0.01 -2.56% 344,447 $0.39 $0.39 $0.38
    11 Feb 2026 $0.39 $0.01 2.63% 174,961 $0.38 $0.40 $0.37
    10 Feb 2026 $0.38 $-0.01 -2.60% 107,007 $0.38 $0.39 $0.37
    09 Feb 2026 $0.39 $0.03 8.33% 93,331 $0.38 $0.39 $0.37
    06 Feb 2026 $0.36 $-0.03 -7.69% 254,693 $0.39 $0.39 $0.36
    05 Feb 2026 $0.39 $-0.01 -2.50% 278,644 $0.40 $0.40 $0.38
    04 Feb 2026 $0.40 $-0.01 -2.41% 138,769 $0.41 $0.41 $0.40
    03 Feb 2026 $0.42 $0.00 0.00% 176,153 $0.42 $0.42 $0.40
    02 Feb 2026 $0.42 $0.00 0.00% 75,053 $0.43 $0.43 $0.42
    30 Jan 2026 $0.42 $-0.03 -6.82% 572,855 $0.44 $0.44 $0.42
    29 Jan 2026 $0.44 $0.01 2.30% 702,938 $0.43 $0.44 $0.43
    28 Jan 2026 $0.44 $0.03 7.32% 561,699 $0.41 $0.45 $0.41

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    04 Dec 2025 Teri Thomas Issued 1,989,189 $984,648
    Issue of securities. 1,989,189 Performance Rights
    06 Nov 2025 Robert Bazzani Buy 100,000 $30,174
    On-market trade.
    30 Jun 2025 Mike Lampron Expiry 1,033,333 $340,999
    As advised by the company. forfeited, 1,189,667 Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Eliot L Siegel Non-Executive Director Aug 2018
    Dr. Siegel is a thought leader in the world of radiology, imaging informatics, and artificial intelligence applications in medicine. He currently serves as a Professor in the Department of Diagnostic Radiology at the University of Maryland School of Medicine and also works for the Veterans Affairs Maryland Healthcare System in Baltimore, MD. Additionally, he holds an adjunct professorship in computer science and biomedical engineering at the undergraduate campuses of the University of Maryland. Dr. Siegel is a pioneer and co-founder of United Theranostics, a company dedicated to bringing state-of-the-art radiopharmaceuticals to patients for cancer therapy. He has also been a leader in national informatics efforts, serving as the informatics lead for the National Cancer Institute's Cancer Biomedical Informatics Grid (caBIG). A prolific author, he has written over 300 articles and book chapters on PACS (Picture Archiving and Communication Systems) and digital imaging. He has also edited books on these topics, including Filmless Radiology and Security Issues in the Digital Medical Enterprise. Dr. Siegel has delivered more than 1,000 presentations globally on a range of subjects related to the use of computers and artificial intelligence in medicine. He served as symposium chairman for the Society of Photo-optical and Industrial Engineers (SPIE) Medical Imaging Meeting for three years. Dr. Siegel currently serves on the board of directors for United Theranostics, ACREW, and Softhread. Former directorships (last 3 years) include Carestream Health. He is Risk Management Committee member.
    Mr Robert John Bazzani Non-Executive ChairmanNon-Executive Director Jan 2020
    Mr. Bazzani spent 20 years with the global consulting firm KPMG, where he rose to the top and served as Chairman of KPMG Victoria, National Managing Partner for KPMG Australia's Enterprise Division and National Managing Partner for KPMG's M&A Division. Whilst in these roles, Rob was a member of KPMG's National Executive Committee (NEC), which oversees and is responsible for the Firm's turnover, strategic decision making, profitability and operations. Rob has a record of leading and growing businesses. He has played a role in advising clients (public, private, and global subsidiaries) on commercial maters, public transitions and corporate governance. Rob has a background in investment banking and law, M&A and has engaged with Government and Regulators. With extensive experience in corporate advisory, Rob has commercial and industry knowledge across financial services, asset and wealth management, technology, property, insurances and consumer & industrial markets. He is Risk Management Committee member.
    Ms Teri Jo Thomas Chief Executive OfficerManaging Director Jul 2025
    --
    Ms Rebecca Thompson Non-Executive Director Nov 2023
    Ms Thompson has more than 25 years of financial markets experience gained at global investment banks, listed companies and a fintech start-up. Rebecca's executive career included seven years at J.P, Morgan as the Head of Corporate Broking followed by a role at KPMG Australia as the Head of Capital Advisory. Rebecca has a skillset across equities, property, and foreign exchange with experience in the real estate, building materials, healthcare, resources and software industries. Stakeholder relations, communications, sustainability and financial analysis are core competencies. Other current directorships include Independent Community Living Australia (ICLA), Non-Executive Director; MarketMeter, Non-Executive Director. She is Risk Management Committee chair.
    Ms Naomi Lawrie Company Secretary Jun 2025
    -
    Dyan O'Herne Chief Financial Officer
    -
    David Madaffri Chief Operating Officer
    -
    Naomi Lawrie Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 46,182,743 19.65%
    Sandhurst Trustees Ltd (Jmfg Consol A/C) 31,838,566 13.55%
    J P Morgan Nominees Australia Pty Limited 26,943,638 11.47%
    Usb Nominees Pty Ltd 11,685,665 4.97%
    Bnp Paribas Noms (Nz) Ltd 7,648,343 3.26%
    Pt Dwi Satrya Utama 4,392,959 1.87%
    Padmalwar Prakash 3,569,921 1.52%
    Microequities Asset Management Pty Ltd (Microeqts Nanocap No 11 A/C) 3,273,641 1.39%
    Chew & Partners (Import & Export) Pte Ltd 2,900,074 1.23%
    Citicorp Nominees Pty Limited 2,673,563 1.14%
    Perco Group Pty Ltd (F S P A/C) 1,981,270 0.84%
    Bpnt Pty Ltd (Heaney Family Super Fund A/C) 1,539,283 0.66%
    Mrs Jennifer Lee Pilcher 1,294,856 0.55%
    Certane Ct Pty Ltd <Hayborough Opp Fund> 1,000,000 0.43%
    62 Darlinghurst Road Pty Ltd 1,000,000 0.43%
    Albert Liong Pak Fai 1,000,000 0.43%
    Hsbc Custody Nominees (Australia) Limited (Gsco Customers A/C) 964,287 0.41%
    Netwealth Investments Limited <Wrap Services A/C> 891,567 0.38%
    Ms Susan Pertile 858,730 0.37%
    Conidico Superannuation Pty Ltd <Conidico Super Fund A/C> 839,444 0.36%

    Profile

    since

    Note